bleomycin hydrolase functions as an MHC class I epitope-processing protease

BH does not play a major role either in generating or destroying class I major histocompatibility antigen (MHC)-presented peptides that bind to the MHC in living cells. These results point to redundant functions between peptidases.

Human Bleomycin Hydrolase (BLMH) Interaktionspartner

Ubc9 plays different roles of action in antitumor agents in chemotherapy. The process requires bleomycin hydrolase and poly(ADP-ribose) polymerase-1. The results are beneficial to deeply understanding of Ubc9 functions and for precise prediction of chemotherapy outcomes in tumors.

The homozygous variant G/G of BLMH gene SNP A1450G is associated with reduced survival and higher prevalence of early relapses in TC patients treated with bleomycin-containing chemotherapy.

BLMH Antigen-Profil

Beschreibung des Gens

Bleomycin hydrolase (BMH) is a cytoplasmic cysteine peptidase that is highly conserved through evolution\; however, the only known activity of the enzyme is metabolic inactivation of the glycopeptide bleomycin (BLM), an essential component of combination chemotherapy regimens for cancer. The protein contains the signature active site residues of the cysteine protease papain superfamily.